{"transactions":[{"id":759124,"issuer":{"id":4567,"kind":"organization","name":"COMPASS Pathways plc"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-05-29T21:16:32.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":21110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":21110,"derivative":{"exercise_price":11.85,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Ordinary Shares","underlying_shares":21110},"source":{"system":"sec-edgar","filing":"0001042021-26-000002","document":"wk-form4_1780089389.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000104202126000002/wk-form4_1780089389.xml","form_type":"4"}},{"id":914857,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:35:38.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":33.2,"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-26-012191","document":"tm265471-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000110465926012191/tm265471-6_4seq1.xml","form_type":"4"}},{"id":914856,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:35:38.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":48.3,"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-26-012191","document":"tm265471-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000110465926012191/tm265471-6_4seq1.xml","form_type":"4"}},{"id":914855,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:35:38.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1920,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":61.9,"underlying":"Common Stock","underlying_shares":1920},"source":{"system":"sec-edgar","filing":"0001104659-26-012191","document":"tm265471-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000110465926012191/tm265471-6_4seq1.xml","form_type":"4"}},{"id":914854,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:35:38.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":265.9,"underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001104659-26-012191","document":"tm265471-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000110465926012191/tm265471-6_4seq1.xml","form_type":"4"}},{"id":914853,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:35:38.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":190,"underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001104659-26-012191","document":"tm265471-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000110465926012191/tm265471-6_4seq1.xml","form_type":"4"}},{"id":914852,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:35:38.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4246,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":45.924,"underlying":"Common Stock","underlying_shares":4246},"source":{"system":"sec-edgar","filing":"0001104659-26-012191","document":"tm265471-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000110465926012191/tm265471-6_4seq1.xml","form_type":"4"}},{"id":914851,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:35:38.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was less than $4.2913 (the \"Cash Amount\") (each such option, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was less than $4.2913 (the \"Cash Amount\") (each such option, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was less than $4.2913 (the \"Cash Amount\") (each such option, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.874,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-012191","document":"tm265471-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000110465926012191/tm265471-6_4seq1.xml","form_type":"4"}},{"id":1010845,"issuer":{"id":4567,"kind":"organization","name":"COMPASS Pathways plc"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-10-31T22:57:23.000Z","date":"2025-10-29","kind":"grant","planned":false,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in 36 equal monthly installments over three years, with the first tranche vesting and becoming exercisable on November 29, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":52000,"derivative":{"exercise_price":6.33,"exercise_date":"2025-11-29","expiration_date":"2035-10-28","underlying":"Ordinary Shares","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001042021-25-000005","document":"wk-form4_1761951440.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000104202125000005/wk-form4_1761951440.xml","form_type":"4"}},{"id":1120140,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T20:05:25.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 4, 2025. The shares underlying the option will fully vest on the earlier of: June 4, 2026 and the date of Generation Bio's 2026 annual meeting of stockholders."}],"balance_after":30000,"derivative":{"exercise_price":0.3874,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-015961","document":"form4-06062025_040613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000141588925015961/form4-06062025_040613.xml","form_type":"4"}},{"id":1483904,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:58:49.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 10, 2025 or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":12500,"derivative":{"exercise_price":10.9,"expiration_date":"2034-06-09","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-24-004953","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218024004953/primarydocument.xml","form_type":"4"}},{"id":1485421,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:05:17.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2024. The shares underlying the option will fully vest on the earlier of: June 6, 2025 and the date of Generation Bio's 2025 annual meeting of stockholders."}],"balance_after":60000,"derivative":{"exercise_price":3.32,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-24-016183","document":"form4-06102024_040613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000141588924016183/form4-06102024_040613.xml","form_type":"4"}},{"id":1573043,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:55.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1904,"price":92.3,"value":175739.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date."}],"balance_after":0,"derivative":{"exercise_price":237.7,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":1904},"source":{"system":"sec-edgar","filing":"0001140361-24-013926","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000114036124013926/form4.xml","form_type":"4"}},{"id":1573042,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:55.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"price":227.04,"value":1135200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":102.96,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001140361-24-013926","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000114036124013926/form4.xml","form_type":"4"}},{"id":1573041,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:55.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8500,"price":201.99,"value":1716915.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":128.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001140361-24-013926","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000114036124013926/form4.xml","form_type":"4"}},{"id":1573040,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Option (right to buy","published_at":"2024-03-18T20:30:55.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":232.41,"value":2905125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":97.59,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001140361-24-013926","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000114036124013926/form4.xml","form_type":"4"}},{"id":1573039,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Option (right to buy","published_at":"2024-03-18T20:30:55.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16250,"price":314,"value":5102500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001140361-24-013926","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000114036124013926/form4.xml","form_type":"4"}},{"id":1573038,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:55.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19893,"price":322.73,"value":6420067.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.27,"expiration_date":"2028-09-30","underlying":"Common Stock","underlying_shares":19893},"source":{"system":"sec-edgar","filing":"0001140361-24-013926","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000114036124013926/form4.xml","form_type":"4"}},{"id":1573037,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T20:30:55.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":990,"price":330,"value":326700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013926","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000114036124013926/form4.xml","form_type":"4"}},{"id":1727101,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-30T21:04:52.000Z","date":"2023-11-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":3935,"price":19.27,"value":75827.45,"ownership":{"direct":true},"balance_after":128046,"source":{"system":"sec-edgar","filing":"0001562180-23-007980","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218023007980/primarydocument.xml","form_type":"4"}},{"id":1727100,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-30T21:04:52.000Z","date":"2023-11-28","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 25, 2020, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 25,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on November 28, 2023, resulting in the vesting of the PSUs as to 10,000 shares."}],"balance_after":131981,"source":{"system":"sec-edgar","filing":"0001562180-23-007980","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218023007980/primarydocument.xml","form_type":"4"}},{"id":1789725,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2023-09-05T20:40:20.000Z","date":"2023-09-01","kind":"exercise","planned":true,"acquired":false,"shares":13809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option vested and became exercisable in eight equal installments on each six month anniversary of the vesting commencement date of September 20, 2018."}],"balance_after":19893,"derivative":{"exercise_price":7.27,"expiration_date":"2028-09-30","underlying":"Common Stock","underlying_shares":13809},"source":{"system":"sec-edgar","filing":"0000950170-23-046439","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023046439/ownership.xml","form_type":"4"}},{"id":1789724,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-09-05T20:40:20.000Z","date":"2023-09-01","kind":"sale","planned":true,"acquired":false,"shares":399,"price":188.98,"value":75403.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.88 to $189.05, inclusive."}],"balance_after":990,"source":{"system":"sec-edgar","filing":"0000950170-23-046439","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023046439/ownership.xml","form_type":"4"}},{"id":1789723,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-09-05T20:40:20.000Z","date":"2023-09-01","kind":"sale","planned":true,"acquired":false,"shares":8423,"price":188.34,"value":1586387.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.87 to $188.84, inclusive."}],"balance_after":1389,"source":{"system":"sec-edgar","filing":"0000950170-23-046439","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023046439/ownership.xml","form_type":"4"}},{"id":1789722,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-09-05T20:40:20.000Z","date":"2023-09-01","kind":"sale","planned":true,"acquired":false,"shares":4387,"price":187.26,"value":821509.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.87 to $187.86, inclusive."}],"balance_after":9812,"source":{"system":"sec-edgar","filing":"0000950170-23-046439","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023046439/ownership.xml","form_type":"4"}},{"id":1789721,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-09-05T20:40:20.000Z","date":"2023-09-01","kind":"sale","planned":true,"acquired":false,"shares":600,"price":186.34,"value":111804.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.84 to $186.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) to this Form 4."}],"balance_after":14199,"source":{"system":"sec-edgar","filing":"0000950170-23-046439","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023046439/ownership.xml","form_type":"4"}},{"id":1789720,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-09-05T20:40:20.000Z","date":"2023-09-01","kind":"exercise","planned":true,"acquired":true,"shares":13809,"price":7.27,"value":100391.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."}],"balance_after":14799,"source":{"system":"sec-edgar","filing":"0000950170-23-046439","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023046439/ownership.xml","form_type":"4"}},{"id":1818241,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2023-08-02T21:53:47.000Z","date":"2023-08-01","kind":"exercise","planned":true,"acquired":false,"shares":13810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option vested and became exercisable in eight equal installments on each six month anniversary of the vesting commencement date of September 20, 2018."}],"balance_after":33702,"derivative":{"exercise_price":7.27,"expiration_date":"2028-09-30","underlying":"Common Stock","underlying_shares":13810},"source":{"system":"sec-edgar","filing":"0000950170-23-037379","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023037379/ownership.xml","form_type":"4"}},{"id":1818240,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-08-02T21:53:47.000Z","date":"2023-08-01","kind":"sale","planned":true,"acquired":false,"shares":600,"price":198.41,"value":119046.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.18 to $198.58, inclusive."}],"balance_after":990,"source":{"system":"sec-edgar","filing":"0000950170-23-037379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023037379/ownership.xml","form_type":"4"}},{"id":1818239,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-08-02T21:53:47.000Z","date":"2023-08-01","kind":"sale","planned":true,"acquired":false,"shares":400,"price":197.66,"value":79064.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.12 to $198.08, inclusive."}],"balance_after":1590,"source":{"system":"sec-edgar","filing":"0000950170-23-037379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023037379/ownership.xml","form_type":"4"}},{"id":1818238,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-08-02T21:53:47.000Z","date":"2023-08-01","kind":"sale","planned":true,"acquired":false,"shares":3110,"price":196.59,"value":611394.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.11 to $197.07, inclusive."}],"balance_after":1990,"source":{"system":"sec-edgar","filing":"0000950170-23-037379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023037379/ownership.xml","form_type":"4"}},{"id":1818237,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-08-02T21:53:47.000Z","date":"2023-08-01","kind":"sale","planned":true,"acquired":false,"shares":6301,"price":195.61,"value":1232538.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.11 to $196.08, inclusive."}],"balance_after":5100,"source":{"system":"sec-edgar","filing":"0000950170-23-037379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023037379/ownership.xml","form_type":"4"}},{"id":1818236,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-08-02T21:53:47.000Z","date":"2023-08-01","kind":"sale","planned":true,"acquired":false,"shares":3399,"price":194.78,"value":662057.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.11 to $195.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (6) to this Form 4."}],"balance_after":11401,"source":{"system":"sec-edgar","filing":"0000950170-23-037379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023037379/ownership.xml","form_type":"4"}},{"id":1818235,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-08-02T21:53:47.000Z","date":"2023-08-01","kind":"exercise","planned":true,"acquired":true,"shares":13810,"price":7.27,"value":100398.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."}],"balance_after":14800,"source":{"system":"sec-edgar","filing":"0000950170-23-037379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023037379/ownership.xml","form_type":"4"}},{"id":1837303,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-07-05T20:44:08.000Z","date":"2023-07-03","kind":"exercise","planned":true,"acquired":false,"shares":13810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option vested and became exercisable in eight equal installments on each six month anniversary of the vesting commencement date of September 20, 2018."}],"balance_after":47512,"derivative":{"exercise_price":7.27,"expiration_date":"2028-09-30","underlying":"Common Stock","underlying_shares":13810},"source":{"system":"sec-edgar","filing":"0000950170-23-031688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023031688/ownership.xml","form_type":"4"}},{"id":1837302,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T20:44:08.000Z","date":"2023-07-03","kind":"sale","planned":true,"acquired":false,"shares":2409,"price":217.82,"value":524728.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.42 to $218.29, inclusive."}],"balance_after":990,"source":{"system":"sec-edgar","filing":"0000950170-23-031688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023031688/ownership.xml","form_type":"4"}},{"id":1837301,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T20:44:08.000Z","date":"2023-07-03","kind":"sale","planned":true,"acquired":false,"shares":3201,"price":216.78,"value":693912.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.37 to $217.35, inclusive."}],"balance_after":3399,"source":{"system":"sec-edgar","filing":"0000950170-23-031688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023031688/ownership.xml","form_type":"4"}},{"id":1837300,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T20:44:08.000Z","date":"2023-07-03","kind":"sale","planned":true,"acquired":false,"shares":7966,"price":215.91,"value":1719939.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.34 to $216.33, inclusive."}],"balance_after":6600,"source":{"system":"sec-edgar","filing":"0000950170-23-031688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023031688/ownership.xml","form_type":"4"}},{"id":1837299,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T20:44:08.000Z","date":"2023-07-03","kind":"sale","planned":true,"acquired":false,"shares":234,"price":214.61,"value":50218.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.05 to $214.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) to this Form 4."}],"balance_after":14566,"source":{"system":"sec-edgar","filing":"0000950170-23-031688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023031688/ownership.xml","form_type":"4"}},{"id":1837298,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T20:44:08.000Z","date":"2023-07-03","kind":"exercise","planned":true,"acquired":true,"shares":13810,"price":7.27,"value":100398.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023."}],"balance_after":14800,"source":{"system":"sec-edgar","filing":"0000950170-23-031688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023031688/ownership.xml","form_type":"4"}},{"id":1846842,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-06-22T20:13:53.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":1904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates."}],"balance_after":1904,"derivative":{"exercise_price":237.7,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":1904},"source":{"system":"sec-edgar","filing":"0000950170-23-029411","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023029411/ownership.xml","form_type":"4"}},{"id":1846841,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-22T20:13:53.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Comprised of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates."}],"balance_after":990,"source":{"system":"sec-edgar","filing":"0000950170-23-029411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000095017023029411/ownership.xml","form_type":"4"}},{"id":1852961,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T20:06:21.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 15, 2024 or the day immediately prior to the 2024 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":56.1,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-23-005263","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218023005263/primarydocument.xml","form_type":"4"}},{"id":1859345,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:15:14.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 8, 2023. The shares underlying the option will fully vest on the earlier of: June 8, 2024 and the date of Generation Bio's 2024 annual meeting of stockholders."}],"balance_after":25000,"derivative":{"exercise_price":4.83,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-23-009607","document":"form4-06122023_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000141588923009607/form4-06122023_040609.xml","form_type":"4"}},{"id":2023246,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-02-10T21:42:31.000Z","date":"2023-02-10","kind":"exercise","acquired":false,"shares":11643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017."}],"balance_after":0,"derivative":{"exercise_price":0.45,"expiration_date":"2023-08-12","underlying":"Common Stock","underlying_shares":11643},"source":{"system":"sec-edgar","filing":"0001562180-23-001257","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218023001257/primarydocument.xml","form_type":"4"}},{"id":2023245,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-10T21:42:31.000Z","date":"2023-02-10","kind":"sale","acquired":false,"shares":3838,"price":44.9007,"value":172328.8866,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $44.815 USD to $45.03 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":121981,"source":{"system":"sec-edgar","filing":"0001562180-23-001257","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218023001257/primarydocument.xml","form_type":"4"}},{"id":2023244,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-10T21:42:31.000Z","date":"2023-02-10","kind":"sale","acquired":false,"shares":7805,"price":44.4694,"value":347083.667,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $43.81 USD to $44.77 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":125819,"source":{"system":"sec-edgar","filing":"0001562180-23-001257","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218023001257/primarydocument.xml","form_type":"4"}},{"id":2023243,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-10T21:42:31.000Z","date":"2023-02-10","kind":"exercise","acquired":true,"shares":11643,"price":0.45,"value":5239.35,"ownership":{"direct":true},"balance_after":133624,"source":{"system":"sec-edgar","filing":"0001562180-23-001257","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218023001257/primarydocument.xml","form_type":"4"}},{"id":2029074,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-07T21:11:19.000Z","date":"2023-02-03","kind":"tax_withholding","acquired":false,"shares":1427,"price":44.16,"value":63016.32,"ownership":{"direct":true},"balance_after":121981,"source":{"system":"sec-edgar","filing":"0001562180-23-001083","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218023001083/primarydocument.xml","form_type":"4"}},{"id":2029073,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-07T21:11:19.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":5100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 10, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 17,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 5,100 shares."}],"balance_after":123408,"source":{"system":"sec-edgar","filing":"0001562180-23-001083","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218023001083/primarydocument.xml","form_type":"4"}},{"id":2063421,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-05T21:29:34.000Z","date":"2023-01-03","kind":"exercise","acquired":false,"shares":2501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option vested in full on February 8, 2020."}],"balance_after":57499,"derivative":{"exercise_price":28.63,"expiration_date":"2026-02-08","underlying":"Common Stock","underlying_shares":2501},"source":{"system":"sec-edgar","filing":"0001562180-23-000234","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218023000234/primarydocument.xml","form_type":"4"}},{"id":2063420,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T21:29:34.000Z","date":"2023-01-03","kind":"exercise","acquired":true,"shares":2501,"price":28.63,"value":71603.63,"ownership":{"direct":true},"balance_after":118308,"source":{"system":"sec-edgar","filing":"0001562180-23-000234","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218023000234/primarydocument.xml","form_type":"4"}},{"id":2230392,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-06-16T20:40:17.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 15, 2023, and (ii) the 2023 annual meeting of the Issuer's stockholders."}],"balance_after":5000,"derivative":{"exercise_price":102.96,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-22-001150","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000159396822001150/primary_01.xml","form_type":"4"}},{"id":2234615,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T20:06:06.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":19200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022. The shares underlying the option will fully vest on the earlier of: June 9, 2023 and the date of Generation Bio's 2023 annual meeting of stockholders."}],"balance_after":19200,"derivative":{"exercise_price":6.19,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":19200},"source":{"system":"sec-edgar","filing":"0001415889-22-006481","document":"form4-06132022_040633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000141588922006481/form4-06132022_040633.xml","form_type":"4"}},{"id":2288069,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-29T12:40:31.000Z","date":"2022-04-27","kind":"exercise","acquired":false,"shares":30944,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017."}],"balance_after":11643,"derivative":{"exercise_price":0.45,"expiration_date":"2023-08-12","underlying":"Common Stock","underlying_shares":30944},"source":{"system":"sec-edgar","filing":"0001562180-22-003565","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218022003565/primarydocument.xml","form_type":"4"}},{"id":2288068,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T12:40:31.000Z","date":"2022-04-27","kind":"exercise","acquired":true,"shares":30944,"price":0.45,"value":13924.8,"ownership":{"direct":true},"balance_after":115807,"source":{"system":"sec-edgar","filing":"0001562180-22-003565","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218022003565/primarydocument.xml","form_type":"4"}},{"id":2386018,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-18T21:10:27.000Z","date":"2022-02-17","kind":"exercise","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017."}],"balance_after":42587,"derivative":{"exercise_price":0.45,"expiration_date":"2023-08-12","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001562180-22-001626","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218022001626/primarydocument.xml","form_type":"4"}},{"id":2386017,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2022-02-18T21:10:27.000Z","date":"2022-02-17","kind":"exercise","acquired":true,"shares":4000,"price":0.45,"value":1800.0,"ownership":{"direct":true},"balance_after":84863,"source":{"system":"sec-edgar","filing":"0001562180-22-001626","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218022001626/primarydocument.xml","form_type":"4"}},{"id":2395033,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T21:41:17.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on February 11, 2022 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 3,800 shares of common stock shall vest on the one year anniversary of February 11, 2022, with 11,400 shares vesting in 36 equal monthly installments thereafter."}],"balance_after":15200,"derivative":{"exercise_price":43.04,"expiration_date":"2032-02-11","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001562180-22-001473","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218022001473/primarydocument.xml","form_type":"4"}},{"id":2537537,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2021-10-21T20:03:09.000Z","date":"2021-10-19","kind":"tax_withholding","acquired":false,"shares":4374,"price":40.29,"value":176228.46,"ownership":{"direct":true},"balance_after":80863,"source":{"system":"sec-edgar","filing":"0001562180-21-006597","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218021006597/primarydocument.xml","form_type":"4"}},{"id":2537536,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2021-10-21T20:03:09.000Z","date":"2021-10-19","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 13, 2019, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 25,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on October 19, 2021, resulting in the vesting of the PSUs as to 10,000 shares."}],"balance_after":85237,"source":{"system":"sec-edgar","filing":"0001562180-21-006597","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218021006597/primarydocument.xml","form_type":"4"}},{"id":2657702,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-06-23T20:28:22.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 16, 2022, and (ii) the 2022 annual meeting of the Issuer's stockholders."}],"balance_after":8500,"derivative":{"exercise_price":128.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001593968-21-001680","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000159396821001680/primary_01.xml","form_type":"4"}},{"id":2664429,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T13:13:30.000Z","date":"2021-06-16","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017."}],"balance_after":46587,"derivative":{"exercise_price":0.45,"expiration_date":"2023-08-12","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001562180-21-004340","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218021004340/primarydocument.xml","form_type":"4"}},{"id":2664428,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2021-06-17T13:13:30.000Z","date":"2021-06-16","kind":"exercise","acquired":true,"shares":12000,"price":0.45,"value":5400.0,"ownership":{"direct":true},"balance_after":75237,"source":{"system":"sec-edgar","filing":"0001562180-21-004340","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218021004340/primarydocument.xml","form_type":"4"}},{"id":2664427,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2021-06-17T13:13:30.000Z","date":"2021-06-15","kind":"tax_withholding","acquired":false,"shares":3093,"price":58.8,"value":181868.4,"ownership":{"direct":true},"balance_after":63237,"source":{"system":"sec-edgar","filing":"0001562180-21-004340","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218021004340/primarydocument.xml","form_type":"4"}},{"id":2664426,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2021-06-17T13:13:30.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 25, 2020, the reporting person was granted Performance Stock Units (PSU) to acquire a total of 25,000 shares of common stock. The PSU vests upon the achievement of certain milestones, one of which was met on June 15, 2021, resulting in the vesting of the PSU as to 10,000 shares."}],"balance_after":66330,"source":{"system":"sec-edgar","filing":"0001562180-21-004340","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218021004340/primarydocument.xml","form_type":"4"}},{"id":2672487,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-11T20:13:29.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2021. The shares underlying the option will fully vest on the earlier of: June 9, 2022 and the date of Generation Bio's 2022 annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":26.59,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-21-002955","document":"form4-06112021_010617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000141588921002955/form4-06112021_010617.xml","form_type":"4"}},{"id":2864058,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-12T21:02:34.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on February 10, 2021 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 8,500 shares of common stock shall vest on the one year anniversary of February 10, 2021, with 25,500 shares vesting in 36 equal monthly installments thereafter."}],"balance_after":34000,"derivative":{"exercise_price":82.27,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001562180-21-001128","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218021001128/primarydocument.xml","form_type":"4"}},{"id":2892502,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-28T21:02:27.000Z","date":"2021-01-27","kind":"exercise","acquired":false,"shares":1800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017."}],"balance_after":58587,"derivative":{"exercise_price":0.45,"expiration_date":"2023-08-12","underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001562180-21-000571","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218021000571/primarydocument.xml","form_type":"4"}},{"id":2892501,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2021-01-28T21:02:27.000Z","date":"2021-01-27","kind":"exercise","acquired":true,"shares":1800,"price":0.45,"value":810.0,"ownership":{"direct":true},"balance_after":56330,"source":{"system":"sec-edgar","filing":"0001562180-21-000571","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218021000571/primarydocument.xml","form_type":"4"}},{"id":3110867,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-15T21:27:04.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on June 11, 2021 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":52000,"derivative":{"exercise_price":19,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0000899243-20-016558","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000089924320016558/doc4.xml","form_type":"4"}},{"id":3119101,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-06-08T20:39:27.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 4, 2021, and (ii) the 2021 annual meeting of the Issuer's stockholders."}],"balance_after":12500,"derivative":{"exercise_price":97.59,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001593968-20-001423","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000159396820001423/primary_01.xml","form_type":"4"}},{"id":3166629,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-30T20:44:51.000Z","date":"2020-04-28","kind":"grant","acquired":true,"shares":15385,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on April 28, 2020 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. 25% of the shares of common stock underlying this stock option award will vest on April 28, 2021, and the remaining 75% of the shares of common stock underlying this stock option award will vest on April 28, 2022, so long as the Reporting Person remains an employee or consultant of the Company on each of the applicable vesting dates."}],"balance_after":15385,"derivative":{"exercise_price":39.87,"expiration_date":"2030-04-28","underlying":"Common Stock","underlying_shares":15385},"source":{"system":"sec-edgar","filing":"0001562180-20-003226","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218020003226/primarydocument.xml","form_type":"4"}},{"id":3271339,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-14T21:56:42.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on February 12, 2020 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 12,500 shares of common stock shall vest on the one year anniversary of February 12, 2020, with 37,500 shares vesting in 36 equal monthly installments thereafter."}],"balance_after":50000,"derivative":{"exercise_price":68.87,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-20-001240","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218020001240/primarydocument.xml","form_type":"4"}},{"id":3346903,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-11T01:04:39.000Z","date":"2019-12-09","kind":"purchase","acquired":true,"shares":7500,"price":64.2,"value":481500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $63.88 USD to $64.49 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":54530,"source":{"system":"sec-edgar","filing":"0001562180-19-005990","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019005990/primarydocument.xml","form_type":"4"}},{"id":3416453,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-12T21:00:17.000Z","date":"2019-09-11","kind":"exercise","acquired":false,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017."}],"balance_after":60387,"derivative":{"exercise_price":0.45,"expiration_date":"2023-08-12","underlying":"Common Stock","underlying_shares":4600},"source":{"system":"sec-edgar","filing":"0001562180-19-004788","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019004788/primarydocument.xml","form_type":"4"}},{"id":3416452,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-09-12T21:00:17.000Z","date":"2019-09-11","kind":"exercise","acquired":true,"shares":4600,"price":0.45,"value":2070.0,"ownership":{"direct":true},"balance_after":47030,"source":{"system":"sec-edgar","filing":"0001562180-19-004788","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019004788/primarydocument.xml","form_type":"4"}},{"id":3454443,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-07-30T00:00:25.000Z","date":"2019-07-25","kind":"tax_withholding","acquired":false,"shares":1685,"price":161.38,"value":271925.3,"ownership":{"direct":true},"balance_after":42430,"source":{"system":"sec-edgar","filing":"0001562180-19-004092","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019004092/primarydocument.xml","form_type":"4"}},{"id":3454442,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-07-30T00:00:25.000Z","date":"2019-07-25","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 13, 2019, the reporting person was granted Performance Stock Units (PSU) to acquire a total of 25,000 shares of common stock. The PSU vests upon the achievement of certain milestones, one of which was met on July 25, 2019, resulting in the vesting of the PSU as to 5,000 shares."}],"balance_after":44115,"source":{"system":"sec-edgar","filing":"0001562180-19-004092","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019004092/primarydocument.xml","form_type":"4"}},{"id":3460171,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-17T20:01:55.000Z","date":"2019-07-16","kind":"exercise","acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option  fully vested on August 12, 2017."}],"balance_after":64987,"derivative":{"exercise_price":0.45,"expiration_date":"2023-08-12","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001562180-19-003968","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003968/primarydocument.xml","form_type":"4"}},{"id":3460170,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-07-17T20:01:55.000Z","date":"2019-07-16","kind":"exercise","acquired":true,"shares":27000,"price":0.45,"value":12150.0,"ownership":{"direct":true},"balance_after":39115,"source":{"system":"sec-edgar","filing":"0001562180-19-003968","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003968/primarydocument.xml","form_type":"4"}},{"id":3474971,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-01T23:17:57.000Z","date":"2019-06-27","kind":"grant","acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 27, 2020, and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":16250,"derivative":{"exercise_price":16,"expiration_date":"2029-06-27","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0000899243-19-018724","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000089924319018724/doc4.xml","form_type":"4"}},{"id":3479263,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-25T21:16:09.000Z","date":"2019-06-21","kind":"grant","acquired":true,"shares":23100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 6, 2017, the reporting person was granted an option to purchase 70,000 shares of common stock. The option vests upon the achievement of certain milestones, one of which was met on June 21, 2019, resulting in the vesting of the option as to 23,100 shares."}],"balance_after":46200,"derivative":{"exercise_price":47.7,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":23100},"source":{"system":"sec-edgar","filing":"0001562180-19-003636","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003636/primarydocument.xml","form_type":"4"}},{"id":3509135,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-29T20:01:38.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":35736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017."}],"balance_after":91987,"derivative":{"exercise_price":0.45,"expiration_date":"2023-08-12","underlying":"Common Stock","underlying_shares":35736},"source":{"system":"sec-edgar","filing":"0001562180-19-003161","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003161/primarydocument.xml","form_type":"4"}},{"id":3509134,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-29T20:01:38.000Z","date":"2019-05-29","kind":"sale","acquired":false,"shares":475,"price":171.3906,"value":81410.535,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This transaction was executed in multiple trades at prices ranging from $171.20 USD to $172.00 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":12115,"source":{"system":"sec-edgar","filing":"0001562180-19-003161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003161/primarydocument.xml","form_type":"4"}},{"id":3509133,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-29T20:01:38.000Z","date":"2019-05-29","kind":"sale","acquired":false,"shares":400,"price":170.395,"value":68158.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This transaction was executed in multiple trades at prices ranging from $170.00 USD to $170.83 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":12590,"source":{"system":"sec-edgar","filing":"0001562180-19-003161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003161/primarydocument.xml","form_type":"4"}},{"id":3509132,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-29T20:01:38.000Z","date":"2019-05-29","kind":"sale","acquired":false,"shares":200,"price":169.16,"value":33832.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This transaction was executed in multiple trades at prices ranging from $168.82 USD to $169.50 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":12990,"source":{"system":"sec-edgar","filing":"0001562180-19-003161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003161/primarydocument.xml","form_type":"4"}},{"id":3509131,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-29T20:01:38.000Z","date":"2019-05-28","kind":"sale","acquired":false,"shares":2545,"price":177.6162,"value":452033.229,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This transaction was executed in multiple trades at prices ranging from $177.18 USD to $177.98 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":13190,"source":{"system":"sec-edgar","filing":"0001562180-19-003161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003161/primarydocument.xml","form_type":"4"}},{"id":3509130,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-29T20:01:38.000Z","date":"2019-05-28","kind":"sale","acquired":false,"shares":11662,"price":176.4426,"value":2057673.6012,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $176.05 USD to $177.01 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":15735,"source":{"system":"sec-edgar","filing":"0001562180-19-003161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003161/primarydocument.xml","form_type":"4"}},{"id":3509129,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-29T20:01:38.000Z","date":"2019-05-28","kind":"sale","acquired":false,"shares":16651,"price":175.718,"value":2925880.418,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $175.05 USD to $176.04 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":27397,"source":{"system":"sec-edgar","filing":"0001562180-19-003161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003161/primarydocument.xml","form_type":"4"}},{"id":3509128,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-29T20:01:38.000Z","date":"2019-05-28","kind":"sale","acquired":false,"shares":28293,"price":174.4837,"value":4936667.3241,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $173.99 USD to $174.93 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":44048,"source":{"system":"sec-edgar","filing":"0001562180-19-003161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003161/primarydocument.xml","form_type":"4"}},{"id":3509127,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-29T20:01:38.000Z","date":"2019-05-28","kind":"sale","acquired":false,"shares":25510,"price":173.6156,"value":4428933.956,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $172.99 USD to $173.98 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":72341,"source":{"system":"sec-edgar","filing":"0001562180-19-003161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003161/primarydocument.xml","form_type":"4"}},{"id":3509126,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-29T20:01:38.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":35736,"price":0.45,"value":16081.2,"ownership":{"direct":true},"balance_after":97851,"source":{"system":"sec-edgar","filing":"0001562180-19-003161","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003161/primarydocument.xml","form_type":"4"}},{"id":3512159,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-24T22:24:56.000Z","date":"2019-05-24","kind":"exercise","acquired":false,"shares":40356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option  fully vested on August 12, 2017."}],"balance_after":127723,"derivative":{"exercise_price":0.45,"expiration_date":"2023-08-12","underlying":"Common Stock","underlying_shares":40356},"source":{"system":"sec-edgar","filing":"0001562180-19-003105","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003105/primarydocument.xml","form_type":"4"}},{"id":3512158,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-24T22:24:56.000Z","date":"2019-05-23","kind":"exercise","acquired":false,"shares":53908,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option  fully vested on August 12, 2017."}],"balance_after":168079,"derivative":{"exercise_price":0.45,"expiration_date":"2023-08-12","underlying":"Common Stock","underlying_shares":53908},"source":{"system":"sec-edgar","filing":"0001562180-19-003105","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003105/primarydocument.xml","form_type":"4"}},{"id":3512157,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-24T22:24:56.000Z","date":"2019-05-24","kind":"sale","acquired":false,"shares":950,"price":177.76,"value":168872.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"This transaction was executed in multiple trades at prices ranging from $177.47 USD to $178.16 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":62115,"source":{"system":"sec-edgar","filing":"0001562180-19-003105","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003105/primarydocument.xml","form_type":"4"}},{"id":3512156,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-24T22:24:56.000Z","date":"2019-05-24","kind":"sale","acquired":false,"shares":2518,"price":176.8,"value":445182.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"This transaction was executed in multiple trades at prices ranging from $176.46 USD to $177.39 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":63065,"source":{"system":"sec-edgar","filing":"0001562180-19-003105","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003105/primarydocument.xml","form_type":"4"}},{"id":3512155,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-24T22:24:56.000Z","date":"2019-05-24","kind":"sale","acquired":false,"shares":3974,"price":175.79,"value":698589.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This transaction was executed in multiple trades at prices ranging from $175.45 USD to $176.42 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":65583,"source":{"system":"sec-edgar","filing":"0001562180-19-003105","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003105/primarydocument.xml","form_type":"4"}},{"id":3512154,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-24T22:24:56.000Z","date":"2019-05-24","kind":"sale","acquired":false,"shares":24966,"price":175.02,"value":4369549.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This transaction was executed in multiple trades at prices ranging from $174.45 USD to $175.43 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":69557,"source":{"system":"sec-edgar","filing":"0001562180-19-003105","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003105/primarydocument.xml","form_type":"4"}},{"id":3512153,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":43270,"kind":"person","name":"JONAS JEFFREY M","position":1,"cik":"0001042021","reported_name":"JONAS JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-24T22:24:56.000Z","date":"2019-05-24","kind":"sale","acquired":false,"shares":7948,"price":174.05,"value":1383349.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This transaction was executed in multiple trades at prices ranging from $173.43 USD to $174.42 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":94523,"source":{"system":"sec-edgar","filing":"0001562180-19-003105","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1042021/000156218019003105/primarydocument.xml","form_type":"4"}}],"next_cursor":"2019-05-24T22:24:56.000000Z,3512153"}